Targeted drug trial aims to control tough cancers by hitting their genetic weakness
NCT ID NCT06390865
Summary
This study is testing if a drug called MLN0128 can help control advanced cancers that have specific genetic changes (TSC1 or TSC2 mutations). The drug works by blocking enzymes that cancer cells need to grow. It is for adults with solid tumors, lymphoma, or multiple myeloma that have not responded to other treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
Conditions
Explore the condition pages connected to this study.